Nicorandil-associated ulcerations

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 5, 2007, Pages 395-398

  Egred, Mohaned ^a  

^a LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

Author keywords

Anal ulceration; Coronary artery disease; Gastrointestinal ulceration; Nicorandil; Oral ulceration; Para stomal ulceration; Potassium channel opener

Indexed keywords

NICORANDIL;

CORONARY ARTERY DISEASE; DISEASE EXACERBATION; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG WITHDRAWAL; FATIGUE; FLUSHING; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; JEJUNUM ULCER; LOW DRUG DOSE; MALAISE; MOUTH ULCER; NAUSEA; ORAL BIOPSY; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; RECTUM BIOPSY; RECTUM ULCER; REVIEW; SIDE EFFECT; TISSUE SECTION; ULCER HEALING;

CORONARY DISEASE; GASTROINTESTINAL DISEASES; HUMANS; NICORANDIL; POTASSIUM CHANNELS; ULCER; VASODILATOR AGENTS;

EID: 34247154741     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328010b184     Document Type: Review

References (36)

1. Frampton J, Buckley M, Fitton A. Nicorandil: a review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs 1992; 44:625-655.
2. Schmid JP, Schroeder V. Nicorandil: review of pharmacological properties and clinical applications. Heart Drug 2005; 5:220-229.
3. The IONA study group. Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomised trial. Lancet 2002; 359:1269-1275.
4. Healy CM, Smyth Y, Flint SR. Persistent nicorandil induced oral ulceration. Heart 2004; 90:e38.
5. Reichert S, Antunes A, Trechot P, Barbaud A, Weber M, Schmutz J. Major aphthous stomatitis induced by nicorandil. Eur J Dermatol 1997;7:132-133.
6. Agbo-Godeau S, Joly P, Szpirglas H. Association of major aphthous ulcers and nicorandil. Lancet 1998; 352:1598-1599.
7. Watson A, Al Ozairi O, Fraser A, Loudon M, O'Kelly T. Nicorandil-associated anal ulceration. Lancet 2002; 360:546-547.
8. Egred M, Andron M, Morrison WL. Nicorandil may be associated with gastrointestinal ulceration. BMJ 2006; 332:889.
9. Abdelrazeq AS, Owen C, Smith L, McAdam JG, Pearson HJ, Leveson SH. Nicorandil-associated para-stomal ulceration: case series. Eur J Gastroenterol Hepatol 2006; 18:1293-1295.
10. Taira N. Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates: an overview. J Cardiovasc Pharmacol 1987; 10 (Suppl 8):S1-S9.
11. Krcyc VAW, Lenz T, Pfrunder D. Mode of action of potassium channel openers in vascular smooth muscle. Rev Contemp Pharmacother 1993;4:185-198.
12. Escande D, Henry P. Potassium channels as pharmacological targets in cardiovascular medicine. Eur Heart J 1983; 14 (Suppl B):2-9.
13. Tamargo J, Caballero R, Gomez R, Valenzuela C, Delpon E. Pharmacology of cardiac potassium channels. Cardio vasc Res 2004; 62:9-33.
14. ATP channels and basal coronary vascular tone. Cardiovasc Res 1994; 28:811-817.
15. ATP channel opener, rilmakalim, in rabbit cardiac cells. Gen Pharmacol 1997; 29:201-205.
16. Garlid KD, Paucek P. Mitochondrial potassium transport: the K( + ) cycle. Biochim Biophys Acta 2003; 1606:23-41.
17. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion: a target for cardioprotection. Cardiovasc Res 2004; 61:372-385.
18. Baumbach A, Braun U, Doring G, Haase KK, VoelkerW, Karsch KR. Double-blind comparison of the acute effects of two relevant doses of oral nicorandil on central hemodynamics, left ventricular function, and myocardial contractility. Cardiovasc Res 1995; 9 (Suppl 2):213-220.
19. Knight C, Purcell H, Fox K. Potassium channel openers: clinical applications in ischemic heart disease - overview of clinical efficacy of nicorandil. Cardiovasc Drugs Ther 1995; 9 (Suppl 2):229-236.
20. Silke B, Verma SP, Ali MS, Goldhammer E, Taylor SH. Effects of nicorandil on left ventricular hemodynamics and volume at rest and during exercise induced angina pectoris. Am J Cardiol 1989; 63:49J-55J.
21. Yokota M, Horisawa T, Iwase M, Miyahara T, Yoshida J, Kamihara S, et al. Effects of a new vasodilator, nicorandil, on exercise-induced impairment of left ventricular function in patients with old myocardial infarction. J Cardiovasc Pharmacol 1987; 10 (Suppl 8):S116-S122.
22. Tsutamoto T, Kinoshita M, Nakac I, Macda Y, Wada A, Yabe T, Horie H. Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure. Am Heart J 1994; 127:866-873.
23. ATP channel activation mediates nicorandil-induced relaxation of nitrate-tolerant coronary arteries. J Cardiovasc Pharmacol 1996; 27:831-837.
24. Frydman A. Pharmacokinetic profile of nicorandil in humans: an overview. J Cardiovasc Pharmacol 1992; 20 (Suppl 3):S34-S44.
25. Frampton J, Buckley MM, Fitton A. Nicorandil: a review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs 1992; 44:625-655.
26. Ronald E. Safety profile of an anti-anginal agent with potassium channel opening activity: an overview. Eur Heart J 1993; 14 (Suppl B):48-52.
27. Witchitz S, Darmon JY. Nicorandil safety in the long-term treatment of coronary heart disease. Cardiovasc Drugs Ther 1995; 9 (Suppl 2):237-243.
28. Vella M, Molloy RG. Nicorandil-associated anal ulceration. Lancet 2002;360:1979.
29. Passeron T, Lacour JP, Mantoux F, Fabiani P, Dubios D, Ortonne JP. Chronic anal ulceration due to nicorandil. Br J Dermatol 2004; 150:394-396.
30. Cribier B, Marquart-Elbaz C, Lipsker D, Alt M, Grosshans E. Chronic buccal ulceration induced by nicorandil. Br J Dermatol 1998; 138:372-373.
31. Desruelles F, Bahadoran P, Lacour JP, Perrin C, Santini J, Ortonne JP. Giant oral aphthous ulcers induced by nicorandil. Br J Dermatol 1998;138:712-713.
32. Marquart-Elbaz C, Lipsker D, Grosshans E, Cribier B. Oral ulcers induced by nicorandil: prevalence and clinico-pathological aspects. Ann Dermatol Venereol 1999; 126:587-590.
33. Laveau F, Chapuis H, Dandurand M, Guillot B. Eosinophilic ulceration of the tongue. Ann Dermatol Venereol 2000; 127:716-718.
34. Prescriptions Pricing Authority NHS. http://www.ppa.org.uk/news/pact- 012001.htm
35. Katory M, Davies B, Kelty C, Arasarandnam R, Skinner P, Brown S, et al. Nicorandil and idiopathic anal ulceration. Dis Colon Rectum 2005;48:1442-1446.
36. King PM, Suttie SA, Jansen JO, Watson AJM. Perforation of the terminal ileum: a possible complication of nicorandil therapy. Surgeon 2004;2:56-57.